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Abstract: Chemerin and its receptor, chemokine-like receptor 1 (CmklR1), are associated with
chemotaxis, inflammation, and endothelial function, especially in metabolic syndrome, coronary
heart disease, and hypertension. In humans, circulating chemerin levels and renal function show
an inverse relation. So far, little is known about the potential role of chemerin in hypertensive
nephropathy and renal inflammation. Therefore, we determined systemic and renal chemerin
levels in 2-kidney-1-clip (2k1c) hypertensive and Thy1.1 nephritic rats, respectively, to explore the
correlation between chemerin and markers of renal inflammation and fibrosis. Immunohistochemistry
revealed a model-specific induction of chemerin expression at the corresponding site of renal damage
(tubular vs. glomerular). In both models, renal expression of chemerin (RT-PCR, Western blot)
was increased and correlated positively with markers of inflammation and fibrosis. In contrast,
circulating chemerin levels remained unchanged. Taken together, these findings demonstrate that
renal chemerin expression is associated with processes of inflammation and fibrosis-related to renal
damage. However, its use as circulating biomarker of renal inflammation seems to be limited in our
rat models.
Keywords: chemerin; CmklR1; 2-kidney-1-clip; 2k1c; Thy1.1 nephritis; renovascular hypertension;
renal inflammation; renal injury; renal fibrosis
1. Introduction
The significance of end-stage renal disease (ESRD) remains clinically relevant due to its high
mortality and morbidity, as well as the lack of effective preventive therapeutic interventions [1].
ESRD results from different forms of renal injury, e.g., arterial hypertension or glomerulonephritis [2,3].
Alterations in the renal microenvironment trigger pathologic immune cell responses with a subsequent
acceleration of progressive renal failure, in the setting of loss of glomeruli, tubular atrophy and
fibrosis, with reduced glomerular filtration rate (GFR) [2,4]. Unfortunately, the molecular pathways
driving persistent renal inflammation are only partly understood to date. Therefore, further research is
warranted regarding the regulatory components of inflammation-induced kidney damage in order
Int. J. Mol. Sci. 2019, 20, 6240; doi:10.3390/ijms20246240 www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2019, 20, 6240 2 of 16
to develop targeted therapeutics to prevent ESRD effectively. Chemokines and cytokines are both
important regulatory mediators of kidney inflammation and potential therapeutic targets [5,6]. They are
produced by resident kidney cells, particularly by podocytes, tubular and mesangial cells, as well as
by microvascular endothelial cells [6]. Certain mediator combinations determine the recruitment of
specific leukocyte subtypes to sites of renal inflammation [2].
Recently, the adipokine chemerin, also known as tazarotene-induced gene 2 protein (TIG2) or
retinoic acid receptor responder protein 2 (RARRES2), was introduced as a novel chemoattractant
protein [7]. It acts as a ligand for the G protein-coupled receptor CmklR1, also known as ChemR23, and
was found to stimulate chemotaxis of dendritic cells and macrophages to sites of inflammation [7,8].
Beyond its classical role in adipogenesis and adipocyte metabolism [9,10], the potential involvement of
chemerin in cardiovascular and renal dysfunction has recently been acknowledged [11]. Chemerin
appears to form an integral link in metabolic syndrome, connecting obesity, the related dysfunctional
cardiometabolic state, and the associated chronic inflammation of adipose tissue [12].
Several investigations have addressed circulating chemerin levels and their pathophysiologic
relevance in cohorts with chronic kidney disease [11]. Unrelated to the method of determination [11],
serum creatinine is significantly and independently associated with serum chemerin [13,14]. The level
of circulating chemerin has been shown to be dependent on GFR and inversely correlated
with renal function. A two-fold increase of serum chemerin has been reported in patients on
hemodialysis [15]. These results were strengthened by an investigation of ESRD-patients undergoing
kidney transplantation [14], whose elevated serum chemerin levels returned to baseline values observed
in healthy controls three months after transplant. Furthermore, elevated chemerin levels persisted
in ESRD patients on hemodialysis compared to healthy controls or kidney transplanted patients.
Nonetheless, hemodialysis reduced high serum chemerin levels to some extent [16]. With adipose
tissue as the main source of circulating chemerin [9], it remains to be determined whether elevated
serum chemerin levels are due to the increase of fat mass in metabolic phenotypes or to the related
renal damage leading to impaired renal elimination. The latter seems more likely [11], as patients with
chronic kidney disease showed no difference in subcutaneous adipose tissue chemerin production
at the mRNA level [16]. However, the role of visceral adipose tissue cannot be completely ruled
out [11]. Also, beyond its role in chemerin elimination, the kidney itself may influence serum chemerin
concentrations via its synthesis, as chemerin expression can be found in animal kidneys [9]. In order to
investigate the role of renal chemerin and its potential use as a diagnostic marker of kidney disease,
our current study characterized its systemic and local expression in established animal models of
hypertensive nephropathy and glomerulonephritis using 2-kidney-1-clip (2k1c) hypertensive and
Thy1.1 nephritic rats, respectively.
2. Results
2.1. Chemerin is Induced in Kidneys Exposed to High Blood Pressure
Five weeks after clipping of the left renal artery, the weights of the contralateral right kidneys
exposed to high blood pressure were significantly higher than the right kidneys of the sham-operated
controls (Table 1). Blood pressure and left ventricular weights of 2k1c rats were increased compared
to controls (Table 1). Serum urea and creatinine, as markers of renal damage, were elevated in
2k1c rats compared to controls (Table 1). The expression levels of chemerin were significantly
higher in the right kidneys of 2k1c hypertensive animals compared to the kidneys of controls
(Figure 1A). Immunohistochemical evaluation of chemerin in kidneys revealed some discrete vascular
and distal tubular staining for chemerin in control kidneys, with a prominent increase in chemerin
immunoreactivity in the tubulo-interstitium of hypertensive kidneys (Figure 1B). The expression of
the chemerin receptor CmklR1 was also induced in hypertensive kidneys (Figure 1C). Moreover, a
Western blot analysis revealed an increase in chemerin protein in hypertensive kidneys (Figure 2).
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Table 1. Physiological parameters of 2k1c experimental groups.
Physiological Parameter Sham 2k1c p-Value
Rel. right kidney weight
(mg/g body weight) 3.21 ± 0.06 4.87 ± 0.25 <0.001
Serum urea
(mg/dL) 37.74 ± 1.13 80.92 ± 11.26 <0.001
Serum creatinine
(mg/dL) 0.195 ± 0.007 0.335 ± 0.038 <0.001
Rel. left ventricular weight
(mg/g body weight) 2.05 ± 0.04 3.03 ± 0.21 0.003
Mean arterial blood
pressure
(mm Hg)
113.2 ± 2.6 203.7 ± 5.0 0.014
Sham, sham-operated control group; 2k1c, hypertensive group. Data are means ± standard error of the mean.
p < 0.05 2k1c versus sham was considered significant.
Int. J. Mol. Sci. 2019, 20, x 3 of 18 
 
Table 1. Physiological parameters of 2k1c experimental groups. 
Physiological Parameter Sham 2k1c p-Value 
Rel. right kidney weight 
(mg/g body weight)  3.21 ± 0.06 4.87 ± 0.25 <0.001 
Serum urea 
(mg/dL) 
37.74 ± 1.13 80.92 ± 11.26 <0.001 
Serum creatinine 
(mg/dL) 
0.195 ± 0.007 0.335 ± 0.038 <0.001 
Rel. left ventricular weight 
(mg/g body weight) 2.05 ± 0.04 3.03 ± 0.21 0.003 
Mean art rial blood pressure 
(mm Hg) 113.2 ± 2.6 203.7 ± 5.0 0.014 
Sham, sham-operated control group; 2k1c, hypertensive group. Data are means ± standard error of 
the mean. p < 0.05 2k1c versus sham was considered significant. 
 
Figure 1. Chemerin and CmklR1 in 2k1c hypertensive nephropathy. (A) Chemerin mRNA expression 
levels in the kidneys of 2k1c hypertensive (2k1c) and control (sham) rats. (B) Exemplary 
photomicrographs of renal tissue from hypertensive (2k1c) and control (sham) rats stained for 
Figure 1. Che and CmklR1 in 2k1c hypertensive nephropat y. (A) Chemerin mRNA
expression levels in the kidneys of 2k1c hypert nsive (2k1c) and c ntrol (sham) rats. (B) Exemplary
photomicrographs of renal tissue from hypertensive (2k1c) and control (sham) rats stained for chemerin.
Black bar represents 100 µm. (C) CmklR1 mRNA expression levels in the kidneys of 2k1c hypertensive
(2k1c) and control (sham) rats. * p < 0.05 vs. sham control kidneys.
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2.2. In Kidneys Exposed to High Blood Pressure, Chemerin Expression Correlates with Markers of Renal
Damage, Inflammation, and Fibrosis
Increased infiltration of M1 and M2 macrophages, neutrophil granulocytes, as well as total
and helper T-cells, but not of cytotoxic T-cells into the right kidneys of 2k1c rats was observed
(Table 2 and Figure 3). Exemplary photomicrographs are shown in Supplementary Figures S1–S3.
The expression of TGFβ-1, a central mediator of tissue fibrosis [17], was upregulated in the kidneys of
2k1c rats (Table 3). Moreover, increased smooth muscle actin expression and the presence of more
smooth muscle actin positive interstitial cells indicate pronounced fibroblast activation [18] in the
right kidney of hypertensive rats (Table 3). Consequently, the expression of the matrix components
fibronectin and collagens I, III, and IV was augmented in the right kidneys of these rats (Table 3).
The expression of collagens I and IV in right kidney tissue was more prominent in 2k1c rats than in
the right kidneys of control rats (Table 3 and Figure 3). Exemplary photomicrographs are shown in
Supplementary Figure S4.
Table 2. Inflammatory cell infiltration in the kidneys of 2k1c.
Cell Type Sham 2k1c p-Value
M2 macrophages
(CD163 pos. cells/cortical view) 0.09 ± 0.04 0.86 ± 0.20 <0.001
Neutrophil granulocytes
(myeloperoxidase pos.
cells/cortical view)
0.53 ± 0.15 1.49 ± 0.30 0.039
Total T-cells
(CD3 pos. cells/cortical view) 1.23 ± 0.47 4.88 ± 1.81 0.046
Helper T-cells
(CD4 pos. cells/cortical view) 11.56 ± 3.37 75.45 ± 14.60 0.002
Cytotoxic T-cells
(CD8a pos. cells/cortical view) 3.12 ± 0.38 4.76 ± 0.35 0.456
Sham, sham-operated control group; 2k1c, hypertensive group. Data are means ± standard error of the mean.
p < 0.05 2k1c versus sham was considered significant.
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Figure 3. M1 macrophage infiltration and expansion of collagen IV in the tubulointerstitial area of rats
with 2k1c hypertensive nephropathy. Sham, control sham operation; ED-1, M1 macrophage marker;
* p < 0.05 vs. sham control kidneys, data are means ± error of the mean.
Table 3. Markers of renal fibrosis in 2k1c.
Fibrotic Marker Sham 2k1c p-Value
TGFβ-1 expression
(fold change) 1.00 ± 0.25 3.69 ± 0.44 0.001
Smooth muscle actin expression
(fold change) 1.00 ± 0.21 5.89 ± 0.96 0.014
Activated fibroblasts
(smooth muscle actin pos. cells/cortical view) 0.26 ± 0.04 5.74 ± 1.50 0.002
Fibronectin expression
(fold change) 1.00 ± 0.24 8.81 ± 1.55 0.003
Collage I expression
(fold change) 1.00 ± 0.32 4.42 ± 0.78 0.024
Collagen I stain
(% pos. cells/cortical view) 4.66 ± 0.44 7.98 ± 1.14 0.001
Colla III ex r ssion
(fold change) 1.00 ± 0.49 18.25 ± 5.32 0.004
Collagen IV expression
(fold change) 1.00 ± 0.22 6.03 ± 0.83 0.001
Sham, sham-operated control group; 2k1c, hypertensive group. Data are means ± standard error of the mean.
p < 0.05 2k1c versus sham was considered significant.
The expression of chemerin in the right kidney of hypertensive rats correlated with serum levels
of urea and creatinine, but not with blood pressure levels (Table 4). There was a correlation between
chemerin expression and M1 macrophage and neutrophil granulocyte infiltration into the right kidneys
(Figure 4). Chemerin expression also correlated with fibroblast activation, TGFβ-1 expression and
the expression of several matrix molecules (Table 4 and Figure 4). Furthermore, there was a high
correlation of chemerin expression with the expression of its receptor CmklR1 (Table 4).
2.3. Chemerin is Induced in Glomeruli Afflicted with Thy1.1 Nephritis and Correlates with Markers of Renal
Damage, Inflammation, and Fibrosis
Two weeks after the induction of a Thy1.1 glomerulonephritis, an increase in serum creatinine and
albuminuria were observed (Table 5). Glomerular M1 macrophage infiltration and renal collagen IV
expression were increased in nephritic kidneys (Figure 5 and Figure S5). Blood pressure was not altered
in Thy1.1 nephritic rats (Table 5). Chemerin expression was increased in the renal tissue of Thy1.1
nephritic rats (Figure 6A). Staining for chemerin revealed prominent glomerular immunoreactivity
in nephritic glomeruli, while in control glomeruli, only some podocytes stained positive (Figure 6B).
The expression of the chemerin receptor CmklR1 was also somewhat increased (Figure 6C).
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Table 4. Correlation of markers of renal damage, inflammation, and fibrosis with chemerin expression
in 2k1c.
Chemerin (mRNA Expression) r p-Value
Serum creatinine (mg/dL) 0.62 0.009
Serum urea (mg/dL) 0.77 <0.001
Mean arterial blood pressure (mm Hg) 0.42 0.12
M1 macrophages (ED-1 pos. cells/view) 0.71 0.001
M2 macrophages (CD163 pos. cells/view) 0.51 0.16
Total T-cells (CD3 pos. cells/view) 0.27 0.40
Cytotoxic T-cells (CD8a pos. cells/view) 0.47 0.11
Helper T-cells (CD4 pos. cells/view) −0.14 0.63
Neutrophil granulocytes (MPO pos. cells/view) 0.83 <0.001
Activated myofibroblasts (SMA-pos. cells/view) 0.74 0.003
Smooth muscle actin (mRNA expression) 0.65 0.005
Fibronectin (mRNA expression) 0.86 <0.001
Collagen I (% pos. area stained) 0.65 0.043
Collagen I (mRNA expression) 0.83 <0.001
Collagen III (mRNA expression) 0.84 <0.001
Collagen IV (% pos. area stained) 0.64 0.014
Collagen IV (mRNA expression) 0.90 <0.001
TGFβ-1 (mRNA expression) 0.73 0.001
CmklR1 (mRNA expression) 0.89 <0.001
r = Spearman–Rho correlation coefficient r, statistical significance was defined as p-value < 0.05.
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Figure 4. Correlation of chemerin expression with infiltration of neutrophilic granulocytes and 1
macrophages and the expression of collagens III and IV. MPO, myeloperoxidase (marker for neutrophil
granulocytes), ED-1, marker for rat M1 macrophages.
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Table 5. Markers of renal damage and blood pressure in Thy1 glomerulonephritis.
Damage Marker NaCl Thy1 p-Value
Rel. right kidney weight
(mg/g body weight) 4.30 ± 0.15 8.57 ± 0.18 <0.01
Albuminuria
(mg/24 h) 0.80 ± 0.19 725.79 ± 303.13 <0.01
Serum creatinine
(mg/dL) 0.19 ± 0.01 0.34 ± 0.03 <0.01
Cytotoxic T-cells
(CD8a pos. cells/cortical view) 3.51 ± 0.56 5.72 ± 0.41 n.s.
Helper T-cells
(CD4 pos. cells/cortical view) 3.05 ± 0.61 6.23 ± 2.39 n.s.
Mean arterial blood pressure
(mm Hg) 118.5 ± 1.5 123.7 ± 6.3 n.s.
Rel. left ventricular weight
(mg/g body weight) 2.23 ± 0.11 2.49 ± 0.09 n.s.
NaCl, NaCl infused control group; Thy1, glomerulonephritic group. Data are means ± standard error of the mean.
p < 0.05 2k1c versus sham was considered significant.
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Figure 5. Glomerular M1 macrophage infiltration and collagen IV expression in the renal cortex of 
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Figure 5. Glomerular M1 macrophage infiltration and collagen IV expression in the renal cortex of rats
with anti-Thy1.1 mesangioproliferative glomerulonephritis. NaCl, control vehicle-injected; ED-1, M1
macrophage marker; ** p < 0.01; data are means ± error of the mean.
The expression of chemerin in kidneys with Thy1.1 glomerulonephritis correlated with serum
creatinine levels, albuminuria, glomerular infiltration of M1 macrophages, and renal collagen IV
expression (Table 6). A correlation between chemerin expression and CmklR1 expression was also
detected (Table 6).
Table 6. Correlation of markers of renal damage, inflammation and fibrosis with chemerin expression
in Thy1 glomerulonephritis.
Chemerin (mRNA Expression) r p-Value
CmklR1 (mRNA expression) 0.89 0.001
Serum creatinine (mg/dL) 0.73 0.017
Albuminuria (mg/24h) 0.73 0.016
Mean arterial blood pressure (mm Hg) 0.42 0.262
M1 macrophages (ED-1 pos. cells/view) 0.72 0.019
Cytotoxic T-cells (CD8a pos. cells/view) 0.58 0.082
Helper T-cells (CD4 pos. cells/view) 0.39 0.266
Collagen IV (mRNA expression) 0.83 0.005
r = Spearman–Rho correlation coefficient r, statistical significance was defined as p-value < 0.05.
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2.4. Chemerin Plasma Levels are Not Increased in Rat Models of Renal Injury
To clarify whether increases of renal tissue chemerin are also reflected by increases in plasma
chemerin, ELISA assays were performed. In 2k1c hypertensive rats, plasma chemerin was not increased
compared to sham-operated controls (1.15 ± 0.06 ng/mL in hypertensive rats versus 1.29 ± 0.11 ng/mL
in controls). Likewise, in Thy1.1 glomerulonephritic rats, plasma chemerin levels were similar to the
plasma levels of control rats (1.13 ± 0.19 ng/mL in nephritic rats versus 1.22 ± 0.10 ng/mL in controls).
3. Discussion
We have demonstrated specific induction of local expression patterns of chemerin related to the
underlying model of renal injury, i.e., tubular-interstitial (2k1c, in kidneys exposed to high blood
pressure) and glomerular damage (Thy1.1 nephritis). In our study, renal chemerin expression positively
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correlated with markers of renal damage and inflammation in 2k1c hypertensive animals and Thy1.1
nephritic rats, indicating a possible involvement of chemerin in these processes, as seen in adipose
tissue [19]. Concomitantly, the expression of the chemerin receptor CmklR1 was also found to be
induced in hypertensive kidneys, while somewhat increased in anti-Thy1.1 treated animals. Of the
three known chemerin receptors (i.e., chemokine-like receptor 1 (CmklR1), G-protein-coupled receptor
(GPR) 1, and C-C motif receptor-like (CCRL) 2, only CmklR1 sufficiently mediates intracellular
signaling functions (reviewed by [12]). Besides its expression in hematopoietic tissues, CmklR1 is
strongly expressed in cells of the immune system (e.g., blood monocytes, monocyte-derived human
macrophages, immature dendritic cells, CD4+ T lymphocytes) [7,20]. CmklR1 directs the migration
of immune cells to lymphoid organs and inflamed tissues [21]. Thus, the observed renal damage in
our models might have partly resulted from chemerin-induced, CmklR1-mediated chemoattraction
of immune cells to the respective sites of renal damage (i.e., tubulo-interstitium in 2k1c model and
glomerulus in Thy1.1 nephritic rats).
Interestingly, CmklR1 expression was additionally observed in human microvascular endothelial
cells (ECs) by Kaur et al. [22]. Thus, para-/autocrine effects of chemerin on renal vasculature in our
model are also possible. Kaur et al. showed that the expression of the receptor was significantly
up-regulated by pro-inflammatory cytokines in human ECs and had strong angiogenic potential via
activation of PI3K/Akt and MAPK pathways in these cells [22]. The involvement of an imbalance of
angiogenesis-related factors in the progression of CKD and the therapeutic potential of modulating
these factors in CKD has been acknowledged (reviewed by [23]). Furthermore, Kaur et al. showed that
chemerin was able to induce the activity of members of the matrix metalloproteinase (MMP) family
in ECs [22], which play an important role in the degradation of the extracellular matrix (ECM) [24].
This effect is also crucial in the development and progression of CKD; however, non-proteolytic
functions of MMPs might also play a role [24]. In line with these observations, we found chemerin to
correlate with markers of renal fibrosis.
So far, the exact mechanisms of renal chemerin induction in our animals remain unknown.
However, a potential role of angiotensin 2 (Ang II) in the regulation of chemerin expression has been
proposed by others. Using a model of diabetic nephropathy, Yu et al. [25] were able to show that the
expression of chemerin in the kidney of diabetic rats was significantly elevated compared to control
animals, suggesting that chemerin might be relevant to the model-specific renal pathology. Treatment
with irbesartan (Ang II type 1 receptor antagonist) appeared to reduce the renal chemerin expression in
these diabetic animals secondary to a reduction in renin–angiotensin system (RAS) components [25].
The Goldblatt 2k1c rat hypertension model is a long-established and widely employed model in
the study of renal artery stenosis and renovascular hypertension [26,27]. We have observed that the
RAS, including Ang II, is closely related with the 2k1c model [28] since their levels are elevated in
the development and maintenance of hypertension in these animals: Early on, hypertension in 2k1c
animals is characterized by increased plasma renin levels in response to low renal arterial pressure and
subsequently by an increase in circulating Ang II. Later, hypertension is maintained by a continuously
activated RAS, as contralateral pressure diuresis of the unaffected kidney prevents hypervolemia [29,30].
Persistent elevation of Ang II also triggers an inflammatory response, characterized by the infiltration of
macrophages (ED-1), tubular overexpression of macrophage chemotactic and adhesion molecules, such
as osteopontin (OPN), MCP-1 and the expression of inflammatory cytokines, ultimately aggravating
renal damage induced by hypertension [3,31,32].
A potential interaction of Ang II with chemerin in the 2k1c model remains to be determined.
Ang II is a key mediator of CKD. A blockade of the Ang II type 1 receptor prevents lethal malignant
hypertension [28]. It is also understood that Ang II mediates renal fibrosis by stimulating the
endogenous synthesis of transforming growth factor-β (TGF-β) [33] in damaged kidney cells, thereby
stimulating the synthesis of the extracellular matrix (ECM), and inhibiting the action of MMPs [34].
TGF-β induces the transformation of fibroblasts into myofibroblasts (α-smooth muscle actin-positive
cells, α-SMA) and stimulates the expression of fibronectin (FN) and collagen type III (Col III).
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This induces the development of renal fibrosis, leads to functional deterioration and increases kidney
damage [34–36]. Notably, we have found that renal chemerin levels correlated positively with these
Ang II-dependent markers of inflammation and fibrosis in both our models of renal injury. Moreover,
other RAS-associated factors, such as aldosterone/mineralocorticoid receptor [37] or the activity of the
angiotensin-converting enzyme (ACE) [38], might be relevant in the function of renal chemerin.
Similar to 2k1c animals, RAS activation also plays a pivotal role in the progression of
glomerulonephritis (GN) in Thy1.1 nephritic rats [39]. Thus, potential cross-talk of chemerin and Ang
II [25] at the glomerular level might be conceivable. The immunohistochemically observed glomerular
expression of chemerin in our Thy1.1 nephritic rats closely resembled glomerular cyto/chemokine
expression patterns typically found in nephritic renal damage [40], thereby underscoring the potential
role of chemerin as a damage-site specific chemoattractant. The most commonly used model of
selective mesangial cell damage [41–43], anti-Thy1.1-induced glomerulonephritis, resembles some
human forms of GN [44], where the renal damage is characterized by the continued accumulation of
ECM, related to the overproduction of glomerular TGF-β.
As a limitation, the role of Ang II in our 2k1c animals and Thy1.1. nephritic rats remains speculative
due to the lack of functional data regarding RAS signaling. Future studies are needed to uncover the
mechanistic insights of chemerin signaling transduction pathways in the kidney, with a special focus
on the exploration of potential therapeutic targets for renal fibrosis and inflammation.
Despite the association of increased chemerin with (renal) inflammation and fibrosis, Yamamoto et
al. found an association of elevated chemerin levels with a survival advantage in dialysis patients [45].
This seems controversial, as CKD induces premature vascular aging with vascular calcification and
increased arterial stiffness [46]. In addition, previous studies had indicated a role of CmklR1 for
the vascular smooth muscle cell (VSMC) atherosclerotic phenotype [47], characterized by vascular
inflammation and intimal hyperplasia [48,49]. Surprisingly, chemerin seemed to inhibit atherogenesis
through CmklR1 [48,50]. Carracedo et al. [51] were able to show that chemerin treatment of
isolated wild-type mouse VSMCs significantly reduced phosphate-induced calcification and increased
expression of the calcification inhibitor matrix-gla-protein (MGP). In contrast, VSMCs of CmklR1
knock-out mice were devoid of these effects. This suggests that elevated chemerin might, in fact, exert
a direct protective vascular role in CKD, while negatively altering the local microenvironment via
attraction of immune cells at the same time.
In contrast to findings in humans [11], we did not observe an induction of circulating chemerin.
So far, the majority of existing human reports focus on elevated circulating levels of chemerin in CKD
patients, while little is known about the local renal expression of the protein. Based on our finding of
increased chemerin expression in ESRD, one could speculate that this may contribute to the reported
increase of circulating chemerin levels in ESRD, apart from the postulated reduced chemerin renal
elimination capacity associated with ESRD [14]. However, as we were unable to detect an increase of
circulating chemerin levels in both animal models of our study, it remains uncertain to what extent such
local changes in our rodent models might translate into a significant increase of circulating chemerin
levels observed in human ESRD.
The lack of increased circulating chemerin seemed unrelated to an inoperative experimental
design. Clipping of the left renal artery and anti-Thy1.1 treatment both sufficiently reduced kidney
function, as determined by a ~2-fold increase in serum urea and creatinine. Also, renal weight was
significantly increased in both rodent models. These results match findings previously obtained by our
group in 2k1c rats [52]. It is possible that despite the detectable renal affliction of our animals and
its correlation with local chemerin expression, the functional renal restriction might not have been
relevant enough to fully resemble the level of kidney failure seen in human ESRD [14]. Thus, the renal
capacity to eliminate increasing levels of circulating chemerin might still have been sufficient in the
examined animal models.
A current methodological limitation in the field of chemerin research is the lack of analysis of
the multitude of existing chemerin pre-cursors [12,19]. Chemerin is proteolytically processed (e.g., by
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cathepsin G, elastase, plasmin, and tryptase) into different active and inactive chemerin peptides, such
as pre-prochemerin and mature prochemerin, which might exert specific functions on their own.
In summary, our findings provide novel evidence that renal chemerin expression in 2k1c and
Thy1.1 nephritic rats are associated with markers of kidney inflammation and fibrosis. However, we
did not find elevated levels of circulating chemerin in these animals. Thus, chemerin might not serve
as a biomarker in these models.
4. Materials and Methods
4.1. Experimental Procedures
All animal experiments were performed in compliance with the DIRECTIVE 2010/63/EU of
the European Parliament and were approved by the local government authorities (Regierung of
Mittelfranken, AZ 54-2532.1-51/12, 22 October 2013 and AZ 55.2.2532-2-526, 18 October 2017). All efforts
were made to minimize suffering in the animal cohort. Rats were housed in a room maintained at 22 ±
2 ◦C, exposed to a 12-h dark/light cycle. The animals had unlimited access to standard rodent nutrition
and tap water.
Induction of hypertensive nephropathy: Two-kidney, one-clip renovascular hypertension (2k1c)
was induced in male Sprague–Dawley rats (Charles River, Sulzfeld, Germany) weighing 150–170 g by
placing a silver clip of 0.2 mm internal diameter around the left renal artery through a flank incision
under isoflurane anesthesia as previously described (n = 25) [53]. Control animals underwent a sham
operation without placement of the clip (n = 10). Analgesia was provided post-operatively in all
animals, and as needed later on. Five weeks after the clipping of the renal artery, the experiment was
terminated, and renal tissue was collected.
Induction of acute glomerulonephritis: Male Sprague-Dawley rats (150 to 200 g) were obtained
from Charles River Deutschland. Anti-Thy1.1 nephritis was induced in uninephrectomized rats by a
single intravenous injection of 1 mg/kg body weight anti-Thy1.1 antibody into the tail vein in light
isoflurane anesthesia. Controls received solvent only (n = 5 per group). The monoclonal antibody
against Thy1.1 (ER4) was from Antibody Solutions (Santa Clara, CA, USA). Anti-Thy1.1 nephritis is an
acute mesangioproliferative glomerulonephritis with mesangial expansion and glomerulosclerosis
peaking at days 7 to 14 of disease [42,54]. On day 13, animals were housed in metabolic cages for 24 h
to collect urine. Five animals per group were sacrificed on day 14 after induction of nephritis and renal
tissue was obtained for further evaluation.
4.2. Blood Pressure Measurements
At the end of the experiment, rats were weighed and instrumented with femoral artery catheters for
intraarterial blood pressure measurements in anesthesia, as described previously [55]. Measurements
were performed on the same day after termination of anesthesia and a recovery phase of 2 h in
conscious animals via transducers connected to a polygraph (Hellige, Freiburg, Germany).
4.3. Measurement of Serum and Urine Parameters
For urine collection, anti-Thy1.1 nephritic animals were put in metabolic cages for 24 h on the
day before sacrifice. Albumin excretion was assessed by enzyme-linked immunosorbent assay (Bethyl
Laboratories, Biomol, Hamburg, Germany). For serum analysis, blood was collected from catheters.
Thereafter, rats were euthanized by bleeding in deep anesthesia. Plasma creatinine and plasma urea
were analyzed using an automatic analyzer Integra 1000 (Roche Diagnostics, Mannheim, Germany).
Plasma chemerin was determined using a commercially available ELISA kit (MyBiosource, Biozol,
Eching, Germany) according to the manufacturer’s protocol.
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4.4. Tissue Sampling
After organ weighing, kidneys were decapsulated. Both poles of each kidney and the apical tip
of the left ventricle were immediately snap-frozen on liquid nitrogen for protein or RNA extraction.
One 6 mm slice of the kidney was put in paraformaldehyde solution (for detection of chemerin), while
another 6 mm slice of the remaining kidney was put in methyl-Carnoy solution (60% methanol, 30%
chloroform and 10% glacial acetic acid) for fixation. After overnight fixation, tissues were dehydrated
by bathing in increasing concentrations of alcohol and embedded in paraffin. Three µm sections were
cut with a Leitz SM 2000 R microtome (Leica Instruments, Nussloch, Germany).
4.5. Immunohistochemistry
Tissue was processed as described [56]. Immunohistochemical detection of chemerin, collagen
I, collagen IV, α-smooth muscle actin (SMA), ED-1, myeloperoxidase (MPO), CD3, CD4, CD8a, and
CD163 was performed in methyl Carnoy-fixed tissue sections. Antibodies used are described in
Supplementary Table S1. The specificity of the chemerin antibody was confirmed by staining in
control tissue: rat skin, lung and testes (see Supplementary Figure S6). Interstitial collagens I and
IV were quantified in 30 medium-power views (magnification x200) by means of an 11 × 11-point
grid or by densitometric analysis using MetaVue software (Molecular Devices, Sunnyvale, CA, USA).
The percentage of grid points corresponding with a stained area or the percentage of stained area in
relation to the total area was calculated. SMA, ED-1, MPO, CD3, CD4, CD8a, and CD163 positive cells
were counted in 20 medium-power cortical views. All histological evaluations were done by a single
investigator blinded to the group assignment.
4.6. Western Blot Analysis
Frozen renal tissue was homogenized, protein samples were prepared as described [57] and
separated on a denaturing SDS-PAGE gel [58]. After electrophoresis, the gels were electroblotted
onto PVDF membranes (Hybond-P, GE Amersham, Munich, Germany), blocked with Rotiblock
(Roth, Karlsruhe, Germany) for 1 h and incubated overnight with a primary antibody to chemerin.
Protein bands were visualized with secondary horseradish peroxidase-conjugated IgG antibodies
(Santa Cruz Biotechnology, 1:50,000), using the Pierce ECL+ system (Thermo Fisher Scientific, Waltham,
MA, USA). Blots were quantified using a luminescent imager (LAS-1000, Fujifilm, Berlin, Germany)
and Aida 2.1 image analysis software (Raytest, Berlin, Germany). Loading of the blot was quantified
by Amido Black staining solution (Sigma, Taufkirchen, Germany).
4.7. Real-Time Polymerase Chain Reaction (PCR) Analyses
Renal tissue was homogenized in RLT buffer reagent (Qiagen, Hilden, Germany) with an ultraturrax
for 30 s, total RNA was extracted from homogenates by RNeasy Mini columns (Qiagen) according
to the manufacturer’s protocol, and real-time RT-PCR was performed [59]. First-strand cDNA was
synthesized with TaqMan reverse transcription reagents (Applied Biosystems, Darmstadt, Germany)
using random hexamers as primers. Reactions without Multiscribe reverse transcriptase were used as
negative controls for genomic DNA contamination. PCR was performed with a StepOnePlus™ sequence
detector system (Applied Biosystems, Darmstadt, Germany) and TaqMan or SYBR Green Universal
PCR master mix (Applied Biosystems), as described previously [57]. All samples were run in duplicates.
Specific mRNA levels in hypertensive animals relative to sham-operated controls were calculated and
normalized to a housekeeping gene (18S) with the ∆∆Ct method as specified by the manufacturer
(Applied Biosystems). Primer pairs used for experiments are shown in Supplementary Table S2.
4.8. Statistical Analysis
Data are expressed as mean ± standard error of the mean (SEM). After testing for normality
distribution using Shapiro–Wilk’s test, we performed Student’s t-test or the Mann–Whitney U-test,
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where appropriate. A p-value < 0.05 was considered significant. To assess correlations between
chemerin and markers of inflammation and fibrosis, Spearman’s correlation coefficients (Spearman’s
rho) were calculated. Calculations were carried out using the SPSS 19 software (IBM, Ehningen,
Germany) and GraphPad Prism 7.00 (GraphPad Software, La Jolla, CA, USA).
Supplementary Materials: Supplementary Materials can be found at http://www.mdpi.com/1422-0067/20/24/
6240/s1. Figure S1: Exemplary photomicrographs of kidneys with 2k1c nephropathy and control kidneys (sham)
stained for the M1 macrophage marker ED1 and the M2 macrophage marker CD163. Figure S2: Exemplary
photomicrographs of kidneys with 2k1c nephropathy and control kidneys (sham) stained for the neutrophil
marker myeloperoxidase and the T-cell marker CD3. Figure S3: Exemplary photomicrographs of kidneys with
2k1c nephropathy and control kidneys (sham) stained for the T-helper cell marker CD4 and the cytotoxic T-cell
marker CD8a. Figure S4: Exemplary photomicrographs of kidneys with 2k1c nephropathy and control kidneys
(sham) stained for collagen I and collagen IV. Figure S5: Exemplary photomicrographs of kidneys with Thy1
induced glomerulonephritis and control kidneys (NaCl) stained for the M1 macrophage marker ED1. Figure S6.
Specificity testing of the chemerin antibody. The antibody stained skin (Luangsay S et al. 2009, J Immunol 183;
Vermi W et al. 2005, J Exp Med 201), lung (Luangsay S et al. 2009, J Immunol 183) and testes (Li L et al. 2014, J
Endocrinol 220), as described before. Black arrowheads point to the chemerin positive keratinocyte layer in a skin
sample, to the chemerin positive ciliated epithelium of the lung bronchioles and to chemerin positive Leydig cells
in testes. Table S1. Antibodies used for immunohistochemistry. Table S2. Primer sequences.
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